Macrilen
Drug
Novo Nordisk Inc
Total Payments
$8.0M
Transactions
1,316
Doctors
710
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $54.22 | 3 | 3 |
| 2023 | $7.9M | 15 | 14 |
| 2022 | $11,252 | 110 | 77 |
| 2021 | $48,704 | 240 | 141 |
| 2020 | $63,030 | 231 | 137 |
| 2019 | $23,270 | 717 | 478 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $7.9M | 1 | 98.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $61,115 | 26 | 0.8% |
| Consulting Fee | $33,324 | 10 | 0.4% |
| Food and Beverage | $32,427 | 1,157 | 0.4% |
| Travel and Lodging | $15,546 | 44 | 0.2% |
| Education | $2,571 | 77 | 0.0% |
| Space rental or facility fees (teaching hospital only) | $1,500 | 1 | 0.0% |
Payments by Type
Research
$7.9M
1 transactions
General
$146,483
1,315 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Diagnosing Adult Growth Hormone Deficiency (AGHD) in Veterans with mTBI using Macimorelin | Novo Nordisk Inc | $7.9M | 0 |
Top Doctors Receiving Payments for Macrilen
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Glendale, AZ | $7.9M | 2 |
| , MBCHB, MD, FRCP(UK) | Endocrinology, Diabetes & Metabolism | Phoenix, AZ | $52,661 | 45 |
| , M.D | Endocrinology, Diabetes & Metabolism | Los Angeles, CA | $19,694 | 20 |
| Tamara Wexler | Internal Medicine | New York, NY | $10,275 | 9 |
| , M. D | Neurology | Galveston, TX | $9,052 | 6 |
| , MD | Endocrinology, Diabetes & Metabolism | San Francisco, CA | $6,614 | 9 |
| , M.D | Internal Medicine | Palo Alto, CA | $6,177 | 7 |
| , M.D | Endocrinology, Diabetes & Metabolism | Plano, TX | $5,130 | 4 |
| , M.D | Endocrinology, Diabetes & Metabolism | Santa Monica, CA | $1,713 | 2 |
| , MD | Endocrinology, Diabetes & Metabolism | Galveston, TX | $1,033 | 4 |
| , MD PHD | Endocrinology, Diabetes & Metabolism | Amarillo, TX | $970.08 | 5 |
| , M.D | Endocrinology, Diabetes & Metabolism | Little Rock, AR | $880.23 | 3 |
| , MD | Endocrinology, Diabetes & Metabolism | Dallas, TX | $772.63 | 3 |
| , M.D | Endocrinology, Diabetes & Metabolism | Amarillo, TX | $732.40 | 4 |
| Eun Kyung Koh | Endocrinology, Diabetes & Metabolism | Tacoma, WA | $378.26 | 5 |
| , MD | Family Medicine | Santa Cruz, CA | $360.32 | 1 |
| , DDS | Periodontics | Briarcliff Manor, NY | $360.32 | 1 |
| , M.D | Pulmonary Disease | Glendale, AZ | $360.32 | 1 |
| , MD | Internal Medicine | Wichita, KS | $347.81 | 13 |
| , MD | Endocrinology, Diabetes & Metabolism | Reno, NV | $339.38 | 4 |
| , M.D | Endocrinology, Diabetes & Metabolism | Tacoma, WA | $313.73 | 3 |
| , MD | Endocrinology, Diabetes & Metabolism | Tacoma, WA | $313.72 | 3 |
| , MD | Endocrinology, Diabetes & Metabolism | Edmond, OK | $306.61 | 1 |
| , DO | Internal Medicine | Mckinney, TX | $294.97 | 1 |
| , M.D | Endocrinology, Diabetes & Metabolism | Mckinney, TX | $294.97 | 1 |
Ad
Manufacturing Companies
- Novo Nordisk Inc $8.0M
Product Information
- Type Drug
- Total Payments $8.0M
- Total Doctors 710
- Transactions 1,316
About Macrilen
Macrilen is a drug associated with $8.0M in payments to 710 healthcare providers, recorded across 1,316 transactions in the CMS Open Payments database. The primary manufacturer is Novo Nordisk Inc.
Payment data is available from 2019 to 2024. In 2024, $54.22 was paid across 3 transactions to 3 doctors.
The most common payment nature for Macrilen is "Unspecified" ($7.9M, 98.2% of total).
Macrilen is associated with 1 research study, including "Diagnosing Adult Growth Hormone Deficiency (AGHD) in Veterans with mTBI using Macimorelin" ($7.9M).